Pacira Pharmaceuticals (82P) Stock Forecast & Price Target
82P Analyst Ratings
Hold
0Buy9Hold0Sell
Based on 9 analysts giving stock ratings to Pacira Pharmaceuticals in the past 3 months
82P Stock 12 Month Forecast
Average Price Target
EUR 31.27▼(-2.89% Downside)Based on 9 Wall Street analysts offering 12 month price targets for Pacira Pharmaceuticals in the last 3 months. The average price target is EUR 31.27 with a high forecast of EUR 32.81 and a low forecast of EUR 22.47. The average price target represents a -2.89% change from the last price of EUR 32.20.
Past 12 Months12 Month ForecastDec2025Sep2026
HighEUR 32.81
AverageEUR 31.27
LowEUR 22.47
Highest Price TargetHighestEUR 32.81Average Price TargetEUR 31.27Lowest Price TargetLowestEUR 22.47
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Hardik Parikh | J.P. Morgan | EUR 20.68→EUR 32.81 | hold | 1.90%Upside | Upgraded | 10/12/26 | ||
| Anish Nikhanj | Truist Financial | EUR 27.87→EUR 32.81 | hold | 1.90%Upside | Downgraded | 10/09/26 | ||
| Douglas Tsao | H.C. Wainwright | EUR 34.16→EUR 32.81 | hold | 1.90%Upside | Downgraded | 10/09/26 | ||
| Daniel Clark | Leerink Partners | EUR 25.17→EUR 32.81 | hold | 1.90%Upside | Reiterated | 10/09/26 | ||
| Serge Belanger | Needham | ― | hold | ― | Downgraded | 10/08/26 | ||
| Dennis Ding | Jefferies | EUR 32.36 | hold | 0.50%Upside | Downgraded | 10/08/26 | ||
| Les Sulewski | Oppenheimer | ― | hold | ― | Downgraded | 10/08/26 | ||
| Douglas Miehm | RBC Capital | EUR 22.47→EUR 32.81 | hold | 1.90%Upside | Assigned | 10/08/26 | ||
| Jenna Davidner | Barclays | EUR 22.47 | hold | -30.21%Downside | Reiterated | 08/17/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Hardik Parikh | 10/12/26 | EUR 20.68→EUR 32.81 | hold | 1.90%Upside | Upgraded | J.P. Morgan | ||
| Anish Nikhanj | 10/09/26 | EUR 27.87→EUR 32.81 | hold | 1.90%Upside | Downgraded | Truist Financial | ||
| Douglas Tsao | 10/09/26 | EUR 34.16→EUR 32.81 | hold | 1.90%Upside | Downgraded | H.C. Wainwright | ||
| Daniel Clark | 10/09/26 | EUR 25.17→EUR 32.81 | hold | 1.90%Upside | Reiterated | Leerink Partners | ||
| Serge Belanger | 10/08/26 | ― | hold | ― | Downgraded | Needham | ||
| Dennis Ding | 10/08/26 | EUR 32.36 | hold | 0.50%Upside | Downgraded | Jefferies | ||
| Les Sulewski | 10/08/26 | ― | hold | ― | Downgraded | Oppenheimer | ||
| Douglas Miehm | 10/08/26 | EUR 22.47→EUR 32.81 | hold | 1.90%Upside | Assigned | RBC Capital | ||
| Jenna Davidner | 08/17/26 | EUR 22.47 | hold | -30.21%Downside | Reiterated | Barclays |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Pacira Pharmaceuticals
3 Months
Success Rate0/2 ratings generated profit
0%
Average Return
-2.95%
Copying Google Drug Manufacturers - Specialty and Generic's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -2.95% per trade.
1 Year
Success Rate1/2 ratings generated profit
50%
Average Return
+19.80%
Copying Google Drug Manufacturers - Specialty and Generic's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +19.80% per trade.
2 Years
Success Rate1/2 ratings generated profit
50%
Average Return
+19.80%
Copying Google Drug Manufacturers - Specialty and Generic's trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +19.80% per trade.
82P Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 3 | 2 | 2 | 2 | 1 |
| Buy | 4 | 4 | 5 | 6 | 6 |
| Hold | 2 | 1 | 2 | 3 | 11 |
| Sell | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 9 | 7 | 10 | 12 | 19 |
In the current month, 82P has received 7 Buy Ratings, 11 Hold Ratings, and 1 Sell Ratings. 82P average Analyst price target in the past 3 months is 31.27.
82P Financial Forecast
ConsensusEUR 0.00
82P Sales Forecast
Next quarter’s sales forecast for 82P is EUR 0 with a range of ― to ―. The previous quarter’s sales results were EUR 171.70M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
82P Stock Forecast FAQ
What is DE:82P’s average 12-month price target, according to analysts?
Based on analyst ratings, Pacira Pharmaceuticals’s 12-month average price target is €31.27.
What is DE:82P’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:82P, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Pacira Pharmaceuticals a Buy, Sell or Hold?
Pacira Pharmaceuticals has a consensus rating of Hold, which is based on 0 buy ratings, 9 hold ratings and 0 sell ratings.
What is Pacira Pharmaceuticals’s share price target?
The average share price target for Pacira Pharmaceuticals is €31.27. This is based on 9 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €32.81, and the lowest forecast is €22.47. The average share price target represents a 2.89% decrease from the current price of €32.2.
What do analysts say about Pacira Pharmaceuticals?
Pacira Pharmaceuticals’s analyst rating consensus is a Hold. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of Pacira Pharmaceuticals?
To buy shares of DE:82P, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.